Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans.
Level 4 - case-series / case-control
Uncontrolled before-and-after interventional study in human cohorts without reported randomization or control group
PubMed 36935449 · doi:10.1007/s10753-023-01801-w
What was done
Healthy younger and older adult cohorts were administered an oral 15-day regimen of 2-hydroxybenzylamine (2-HOBA) acetate. Plasma inflammatory biomarkers were measured before and after treatment using the Olink targeted inflammation panel, followed by Ingenuity Pathway Analysis.
What was found
The abstract reports significant relative changes in 15 plasma immune proteins after 15 days of 2-HOBA treatment. Specific reported alterations included significant increases in CCL19, IL-12β, IL-20Rα, and TNFβ, along with a significant decrease in TWEAK. No exact numerical concentrations, baseline values, effect sizes, or p-values are reported in the abstract.
Why it matters
This study provides early in vivo human evidence that oral 2-HOBA alters circulating immune and inflammatory signaling proteins.
Limits
The abstract does not state the sample size (n), dosage, or whether there was a placebo control group. The study evaluated short-term surrogate blood biomarkers in healthy participants rather than clinical outcomes.
Cited by
- supports 2-hydroxybenzylamine (2-HOBA), a compound studied for treating hypertension via immune-vascular signaling, is found in only one food: Tartary buckwheat.